- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SPAGO NANOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 20.08. | Spago Nanomedical Interim Report January-June, 2025 | 209 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 20, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)APRIL - JUNE IN BRIEFNet sales for the quarter amounted to KSEK 81 (KSEK 459)The loss for the quarter amounted... ► Artikel lesen | |
| 03.06. | Spago Nanomedical Continues Patient Recruitment in the Phase I/IIa Study Tumorad-01 as Planned after DMC Recommendation | 245 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 3, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - Spago Nanomedical AB (publ) announced today that the Data Monitoring Committee (DMC) recommends the ongoing... ► Artikel lesen | |
| 14.05. | Bulletin from the 2025 Annual General Meeting of Spago Nanomedical AB | 268 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 14, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - The Annual General Meeting (AGM) of Spago Nanomedical AB (publ) was held today, May 14, 2025, at which the AGM... ► Artikel lesen | |
| 07.05. | Spago Nanomedical Interim Report January-March, 2025 | 300 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 7, 2025 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F)OCTOBER - DECEMBER IN BRIEFNet sales for the quarter amounted to KSEK 338 (KSEK 350)The loss for the quarter amounted... ► Artikel lesen | |
| 15.04. | Spago Nanomedical Publishes The Annual Report for 2024 | 307 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 15, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)Spago Nanomedical's annual report for 2024 is from today available at the company's website, https://spagonanomedical.se/investor-relations/financial-reportsFor... ► Artikel lesen | |
| 09.04. | Notice To Annual General Meeting of Spago Nanomedical AB | 322 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 9, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)This English version of the notice to the Annual General Meeting is for convenience only. The Swedish version... ► Artikel lesen | |
| 04.04. | Spago on the increased dose in Tumorad-01 | 2 | Cision News | ||
| 20.03. | Nomination Committee's Proposal for a New Chairman and Composition of Spago Nanomedical's Board | 633 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 20, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the company's nomination committee proposes a changed board... ► Artikel lesen | |
| 04.03. | Spago Nanomedical Proceeds with Increased Dose in the Phase I/IIa study Tumorad-01 | 328 | ACCESS Newswire | LUND, SE / ACCESSWIRE / March 04, 2025 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the independent Data Monitoring Committee (DMC) recommends a dose... ► Artikel lesen | |
| 06.02. | Spago Nanomedical year-end report January-December, 2024 | 271 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 6, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)OCTOBER - DECEMBER IN BRIEFNet sales for the quarter amounted to KSEK 617 (KSEK 731)The loss for the quarter... ► Artikel lesen | |
| 15.01. | Spago Nanomedical Article on SPAGOPIX-01 Clinical Results Accepted for Publication in Investigative Radiology | 245 | ACCESS Newswire | LUND, SWEDEN / ACCESSWIRE / January 15, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that a manuscript on product candidate pegfosimer manganese has... ► Artikel lesen | |
| 18.12.24 | Second Patient Group Successfully Dosed in Spago Nanomedical's Phase I/IIa Study Tumorad-01 | 429 | ACCESS Newswire | LUND, SE / ACCESSWIRE / December 18, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) today announced that all patients in the second patient group have been dosed according... ► Artikel lesen | |
| 06.11.24 | Spago Nanomedical Interim Report January-September 2024 | 287 | ACCESS Newswire | LUND, SWEDEN / ACCESSWIRE / November 6, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Progress for the Tumorad programJULY - SEPTEMBER IN BRIEFNet sales for the quarter amounted to KSEK 485 (KSEK... ► Artikel lesen | |
| 21.10.24 | Nomination Committee Appointed for Spago Nanomedical's Annual General Meeting 2025 | 281 | ACCESS Newswire | LUND, SE / ACCESSWIRE / October 21, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) In accordance with the instructions to the nomination committee resolved by the Annual General Meeting ("AGM")... ► Artikel lesen | |
| 01.10.24 | Spago Nanomedical in New Phase with Full Focus on the Tumorad Program | 356 | ACCESS Newswire | LUND, SWEDEN / ACCESSWIRE / October 1, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) The Board of Directors of Spago Nanomedical AB (publ) has decided that the company's resources will be focused... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,345 | -0,43 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Dies schrieb Analyst Tycho Peterson in seinem am Freitag... ► Artikel lesen | |
| BIONTECH | 87,65 | +0,40 % | BioNTech: Chancen in Onkologie, Sorgen im Kurs | Die Aktie von BioNTech SE notiert aktuell bei 94,73 EUR. Nach dem beispiellosen Erfolg mit dem COVID-19-Impfstoff steht das Mainzer Biotech-Unternehmen vor der Herausforderung, seine Pipeline in Onkologie... ► Artikel lesen | |
| TOURMALINE BIO | 47,600 | +57,41 % | Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen | DJ Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen
Von Adam Whittaker
DOW JONES--Novartis will das US-Biopharmaunternehmen Tourmaline Bio für rund 1,4 Milliarden US-Dollar... ► Artikel lesen | |
| ISPECIMEN | 3,180 | +337,17 % | iSpecimen Inc.: iSpecimen Approached by Crypto Currency Companies for $200 Million Treasury Discussions | Woburn, Massachusetts--(Newsfile Corp. - September 4, 2025) - iSpecimen Inc. (NASDAQ: ISPC), (the "Company"), a technology-enabled company modernizing the way human biospecimens are sourced for scientific... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 28,005 | -11,07 % | Rapport Therapeutics, Inc.: Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures | Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving... ► Artikel lesen | |
| EVOTEC | 5,810 | -1,02 % | INSIDERALARM bei Evotec! Valneva mit neuem KURSZIEL! Vidac Pharma Aktie bald mit neuem ALLZEITHOCH? | Endlich! Bei Evotec sorgen Insider für ein wichtiges Signal. Die Aktie reagiert zwar noch nicht, aber mittelfristig könnte sich dies als Kaufsignal herausstellen. Derzeit herrscht noch Skepsis. Bullish... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,915 | -2,75 % | Is Summit Therapeutics a Buy, Sell, or Hold Now? | ||
| RECURSION PHARMACEUTICALS | 4,660 | +0,76 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 46,690 | -2,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 17,810 | +2,71 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 33,810 | -5,66 % | Harmony Biosciences: Wachstumsstrategie und Pipeline-Fortschritte im Fokus | ||
| JYONG BIOTECH | 51,63 | -6,13 % | Jyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering | New Taipei City, Taiwan, June 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (the "Company"), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 37,330 | +3,87 % | H.C. Wainwright reiterates Buy rating on Mineralys stock, citing lorundrostat potential | ||
| MODERNA | 21,005 | +1,94 % | Leichte Zugewinne bei der Moderna-Aktie (21,325 €) | Der Anteilsschein von Moderna notiert am Freitag etwas fester. Das Papier notiert aktuell bei 21,33 Euro. Für der Anteilsschein von Moderna steht gegenwärtig ein Wertanstieg 4,08 Prozent zu Buche. Das... ► Artikel lesen | |
| VERA THERAPEUTICS | 24,960 | +0,85 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen |
SPAGO NANOMEDICAL AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (-1,96 %) liegt der Kurs bei 0,020 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPAGO NANOMEDICAL AB finden Sie auf Wallstreet Online.